The anti-ERBB2 antibody, trastuzumab, was developed to treat ERBB2-positive breast cancer. The cardiac toxicity it produced was unexpected but led to new insights about a role for ERBB2 in the resp ...

ERBB2 is required for CM proliferation and heart integrity in neonates. We first sought to determine the effect of NRG1 on CM proliferation during the transient postnatal regenerative window in ...

For Older Women with ERBB2-Positive Breast Cancer, Some Encouraging News —A new study shows that racial and ethnic disparities among Medicare beneficiaries who receive ERBB2 (formerly HER2 ...

Lapatinib exhibited preliminary evidence of biologic and clinical activity in ErbB1 and/or ErbB2-overexpressing tumors. However, the limited sample size of this study and the variability of the ...

ErbB2 Inhibitor. Presentation ID: PO3-26-02Title: Identification of a novel, brain penetrant, EGFR sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutationsSession: ...

Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine ...

Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2 ...

ERBB2 mutations were detected in 18 patients (7.7%). One patient had 2 distinct ERBB2 mutations, a total of 19 identified for analysis. Located in the juxtamembrane domain, the most common ...

TOPLINE: Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated with improved overall survival in patients with early-stage ERBB2-positive breast cancer.

FDA Approves First NGS-Based Companion Diagnostic to Aid in Selecting Non-Small Cell Lung Cancer Patients with HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment with ENHERTU ...

Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently ...